Intellia Therapeutics(NTLA) - 2025 Q2 - Quarterly Results

Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress Exhibit 99.1 CAMBRIDGE, Mass., Aug. 7, 2025 – Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today reported operational highlights and financial results for the second quarter ended June 30, 2025. "We are exceeding many of our internal expectations," said Intellia President and Chief Executive O ...